Young patients suffering from two aggressive sarcoma types can now participate in the innovative PAMSARC therapy study at the NCT Heidelberg. The study uses molecular biological methods and tests the extent to which a new drug can improve the poor prognosis for these tumours.

Winfried Kretschmann, the Minister President of Baden-Württemberg, Germany, visited the Max Planck Institutes for Biology Tübingen and Biological Cybernetics. During his tour, he commended the outstanding basic research in the natural sciences. He was particularly impressed by the innovative research projects spanning developmental and evolutionary biology, as well as neuroscience.

Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging and re-emerging viruses.

University of Tübingen research team observes biochemical process in living cells – indications of new approach to preventing heart attacks and strokes

If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University discovered that the correct development of functioning blood vessels in the mouse placenta is controlled epigenetically: One of the enzymes that modify gene activity using methyl groups is responsible.

Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of "DNA origami". The system they developed may facilitate the transportation of large therapeutic loads into cells. This opens up a new way for the targeted administration of medication and other therapeutic interventions.

The MedTech company KARL STORZ announces the acquisition of the innovative software manufacturer Innersight Labs Ltd. (ISL) headquartered in London. In addition to state-of-the-art endoscopes, high-end medical devices, and integrated solutions for the operating room, KARL STORZ is also continuing to expand in innovative software solutions. Its large customer base, including top-class physicians worldwide, can now look forward to 3D models.

A research team from Freiburg and Frankfurt has discovered how cells recognise and internally break down waste. The results are relevant for the development of therapies for diseases such as Alzheimer’s.

Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the DKFZ, the Heidelberg Stem Cell Institute HI-STEM and the NCT Heidelberg has now succeeded for the first time in cultivating stable tumor organoids directly from blood samples of breast cancer patients.

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December 2024.

UKCA product marking - 18/12/2024

New medical device marking requirements and regulations in Great Britain

Since Brexit, additional regulations for medical devices have come into effect in Great Britain, i.e. England, Wales and Scotland. Although the transition periods have been extended, medical device manufacturers should familiarise themselves with the new conformity marking requirements. EU medical device regulations will continue to apply in Northern Ireland.

Expert interview - 16/12/2024

Learning from Nature for Innovation

Natural phenomena are used to find technological solutions in a number of fields. In an interview with BIOPRO, Prof. Dr. Peter M. Kunz discusses groundbreaking innovations emerging from Baden-Württemberg and shares insights on how the principles of bionics can inspire the next generation of innovators.

Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.

The Gottfried Wilhelm Leibniz-Prize 2025 goes to Prof. Dr Robert Zeiser for his outstanding research in haematology and immunology. Zeiser’s research at the University of Freiburg and the Medical Center – University of Freiburg have led, among other things, to new types of cancer therapy that has increased survival rates and the patients’ quality of life.

Transcranial magnetic stimulation (TMS) - 10/12/2024

sync2brain: using magnetic waves to combat depression

In cases where standard therapies for mental illnesses such as depression prove ineffective, transcranial magnetic stimulation (TMS) offers a promising alternative. This method uses magnetic pulses to stimulate specific regions of the brain. The company sync2brain has developed a system that leverages EEG measurements to tailor stimulation to each patient's unique brain wave patterns, that may significantly enhance the therapy's…

Researchers at the Medical Faculty of Heidelberg University and the Heidelberg University Hospital have used modified rabies viruses to label glioblastoma tumour cells and their direct cell contacts in the mouse brain. The new method showed that the tumour cells are connected to different types of nerve cells throughout the entire brain at a very early stage of the disease.